


MALEIMIDE-FUNCTIONALISED LIPOSOMES AS MUCOADHESIVE VEHICLES FOR DRUG DELIVERY TO URINARY BLADDER

Daulet Kaldybekov, Vitaliy Khutoryanskiy






International Agency for Research on Cancer



World cancer factsheet

January 2014

World cancer burden (2012)



Bladder cancer has the 9th highest incidence rate worldwide, with a greater prevalence among men than women.


In the UK:

- § 10,100 new cases of bladder cancer in 2014, that's 28 cases diagnosed every day.
- § BC is the 10th most common cancer (2014).
- § In males, BC is the eight most common cancer and 14th in females

https://www.iarc.fr




Urinary bladder: intravesical delivery



- Normal capacity: 400–600 mL;
- 150–300 mL triggers the urge to urinate;
- Urinary bladder wall is highly impermeable



Bladder cancer




Intravesical therapy is used only for non-invasive (stage 0) or minimally invasive (stage I) bladder cancers.

Intravesical immunotherapy: Bacillus Calmette-Guerin (BCG)


Intravesical chemotherapy: Mitomycin, valrubicin, doxorubicin, and gemcitabine







Types of liposomes




- Non-toxicity, biocompatible, and completely biodegradable
- q Increasing drug efficacy
- **q** Site avoidance effect
- Increasing stabilityvia encapsulationprocess
- Reducing the toxicity of encapsulated drugs



THE COMPOSITION OF LIPOSOMAL FORMULATIONS


Liposome formulations	PC (%)	Chol (%)	PEG ₂₀₀₀ -DSPE (%)	PEG ₂₀₀₀ -DSPE-Mal (%)	NaFlu (%)
Conventional	0.773	0.077	-	-	0.2
PEGylated	0.773	0.077	0.075	-	0.2
PEG-Mal	0.773	0.077	-	0.075	0.2








PHYSICOCHEMICAL CHARACTERISTICS

Liposome formulations	Mean diameter (nm)	PDI	Zeta potential (mV)	%EE	%LC
Conventional	97 ± 1	0.145	-53 ± 1	53 ± 6	12 ± 1
PEGylated	85 ± 1	0.217	-32 ± 2	27 ± 2	6 ± 1
PEG-Mal	86 ± 1	0.224	-37 ± 1	25 ± 2	5 ± 1










Conventional liposomes

PEGylated liposomes

PEG-maleimide liposomes




Application of mucoadhesive onto a bladder mucosa






Exemplary fluorescent images of the retention of formulations on urinary bladder mucosa











WASH OUT₅₀ PROFILES



Wash Out ₅₀ (WO ₅₀) values are defined as the
volume of liquid necessary to remove 50% of
a mucoadhesive material from a substrate

Formulations	WO ₅₀ , mL	
Conventional	15	
PEGylated	24	
PEG-Mal	48	
FITC-chitosan	91	
FITC-dextran	5	




Proposed mechanism of bonding between maleimidefunctionalised liposomes and mucosal surfaces





Penetration into bladder mucosa


Exemplary fluorescence microscopy images:












Maleimide-terminated PEG liposomes







Toxicity - Slug mucosal irritation test

METHOD:








Kept in desiccators lined with paper towels soaked with 20 mL of PBS at RT for 48 h

 $Slugs\,sourced\,from\,Harris\,Garden,\,UoR$



weighed before the experiment




filter paper moistened with test materials







Left to contact for 1 h





rinsed and wiped







Mucus production:

$$MP = \frac{(m_b - m_a)}{m_b} \times 100\%$$

re-weighed





BAC – Benzalkonium chloridePBS – Phosphate buffered saline

PEG – Poly(ethylene glycol) methyl ether (average Mn 5,000)
PEG-Mal - Methoxypolyethylene glycol maleimide (average Mn 5,000)

MHA – 6-Maleimidohexanoic acid

Results published in

Eur. J Pharm. Sci. 2018, 111, 83-90



Acknowledgements

Sponsor:





THANK YOU!